NVVE secures Nasdaq Panel extension amid $1 bid, $2.5M equity gaps

Rhea-AI Filing Summary

Nuvve Holding Corp. (NVVE) received a Nasdaq compliance extension after a hearing with the Nasdaq Hearings Panel. The Panel granted the company until December 31, 2025 to regain compliance, subject to conditions.

The extension follows earlier notices that NVVE’s stock closed below $1.00 for 30 consecutive trading days under the Bid Price Rule and that it was also noncompliant with the $2,500,000 minimum stockholders’ equity requirement. Nasdaq indicated NVVE was not eligible for a standard cure period due to prior reverse stock splits over the last two years with a cumulative ratio of 250-to-1 or more. NVVE plans to pursue its compliance plan, but there is no assurance it will regain or maintain its listing.

Positive

• None.

Negative

• Nasdaq noncompliance with $1.00 bid price and $2,500,000 equity rules raises delisting risk despite temporary extension

Insights

Exchange compliance analyst

Nasdaq grants NVVE until Dec 31, 2025 to fix bid price and equity deficiencies.

Nuvve remains out of compliance with the $1.00 Bid Price Rule and the $2,500,000 stockholders’ equity requirement. The company obtained a Panel-approved extension to pursue its plan to regain compliance, which keeps suspension at bay during the process.

The Panel noted NVVE’s prior reverse splits within two years totaling a 250-to-1 ratio, which removed eligibility for standard compliance periods. The extension is conditional; failure to meet conditions by December 31, 2025 could lead to delisting.

Key dependencies are execution of the company’s plan and market performance. The filing states there is no assurance of success, so actual impact will hinge on whether NVVE satisfies the Panel’s conditions by the deadline.

false000183687500018368752025-10-282025-10-280001836875us-gaap:CommonStockMember2025-10-282025-10-280001836875us-gaap:WarrantMember2025-10-282025-10-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

_________________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 28, 2025

NUVVE HOLDING CORP.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-40296

86-1617000

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

2488 Historic Decatur Road, Ste 230

San Diego,

California

92106

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (619) 456-5161

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbols

Name of each exchange on which registered

Common Stock, Par Value $0.0001 Per Share

NVVE

The Nasdaq Stock Market LLC

Warrants to Purchase Common Stock

NVVEW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.        o

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on August 27, 2025, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company was no longer in compliance with the requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Bid Price Rule”). Further, the Notice stated that, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for any compliance period specified in Rule 5810(c)(3)(A) due to the fact that the Company has effected a reverse stock split over the prior one-year period and has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The Notice also stated that since the Company remains noncompliant with the $2,500,000 minimum stockholders’ equity rule under Listing Rule 550(b)(1) (the “Equity Rule”), such noncompliance with the Equity Rule serves as an additional and separate basis for delisting.

On September 3, 2025, the Company timely requested a hearing with the Nasdaq’s Hearings Panel (the “Panel”), which request stayed any further suspension or delisting action by Nasdaq at least pending the ultimate conclusion of the hearing process. On October 28, 2025, the Panel informed the Company that it had granted the Company’s requested extension to regain compliance by December 31, 2025, subject to certain conditions and requirements as a result of the hearing with the Panel. While the Company intends to pursue its plan to regain compliance as presented to the Panel, there can be no assurance that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq.

Forward-Looking Statements

This Current Report on Form 8-K contains certain “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company’s intent or ability to regain compliance with the Bid Price Rule and/or the Equity Rule, the outcome of any Nasdaq appeal process and the Company’s intent or ability to maintain the Common Stock’s listing on Nasdaq. All forward-looking statements reflect the Company’s beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
104						Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 31, 2025

			NUVVE HOLDING CORP.
			By:			/s/ Gregory Poilasne
						Gregory Poilasne
						Chief Executive Officer

2

FAQ

What did Nuvve (NVVE) announce regarding its Nasdaq listing?

A Nasdaq Hearings Panel granted NVVE an extension until December 31, 2025 to regain compliance with listing standards.

Which Nasdaq rules is NVVE currently not meeting?

NVVE is noncompliant with the $1.00 Bid Price Rule and the $2,500,000 minimum stockholders’ equity requirement.

Why didn’t NVVE receive a standard compliance period?

Nasdaq cited prior reverse stock splits within two years totaling a 250-to-1 cumulative ratio, which removed eligibility for standard cure periods.

What happens if NVVE does not regain compliance by the deadline?

Failure to meet the Panel’s conditions by December 31, 2025 could result in delisting.

Does NVVE guarantee it will maintain its Nasdaq listing?

No. The company stated there is no assurance it will regain compliance or maintain its listing.

What is the immediate impact of the Panel process on trading?

The hearing request stayed further suspension or delisting actions during the process, pending the Panel’s conclusion and conditions.